AU2007310845A1 - Use of MTKI 1 for treating or preventing bone cancer - Google Patents

Use of MTKI 1 for treating or preventing bone cancer Download PDF

Info

Publication number
AU2007310845A1
AU2007310845A1 AU2007310845A AU2007310845A AU2007310845A1 AU 2007310845 A1 AU2007310845 A1 AU 2007310845A1 AU 2007310845 A AU2007310845 A AU 2007310845A AU 2007310845 A AU2007310845 A AU 2007310845A AU 2007310845 A1 AU2007310845 A1 AU 2007310845A1
Authority
AU
Australia
Prior art keywords
bone
cancer
compound
methyl
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007310845A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Michel Marie Francois Janicot
Theo Frans Meert
Timothy Pietro Suren Perera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2007310845A1 publication Critical patent/AU2007310845A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2007310845A 2006-10-27 2007-10-25 Use of MTKI 1 for treating or preventing bone cancer Abandoned AU2007310845A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US86316706P 2006-10-27 2006-10-27
EP06123060.3 2006-10-27
EP06123060 2006-10-27
US60/863,167 2006-10-27
US97618807P 2007-09-28 2007-09-28
US60/976,188 2007-09-28
PCT/EP2007/061501 WO2008049904A2 (en) 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer

Publications (1)

Publication Number Publication Date
AU2007310845A1 true AU2007310845A1 (en) 2008-05-02

Family

ID=39066650

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007310845A Abandoned AU2007310845A1 (en) 2006-10-27 2007-10-25 Use of MTKI 1 for treating or preventing bone cancer

Country Status (11)

Country Link
EP (1) EP2101782A2 (ja)
JP (1) JP2010507628A (ja)
KR (1) KR20090086977A (ja)
AU (1) AU2007310845A1 (ja)
BR (1) BRPI0718021A2 (ja)
CA (1) CA2664165A1 (ja)
EA (1) EA200970420A1 (ja)
IL (1) IL198344A0 (ja)
MX (1) MX2009004438A (ja)
NO (1) NO20092059L (ja)
WO (1) WO2008049904A2 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
NO20092059L (no) 2009-06-29
MX2009004438A (es) 2009-05-11
KR20090086977A (ko) 2009-08-14
JP2010507628A (ja) 2010-03-11
IL198344A0 (en) 2010-02-17
EA200970420A1 (ru) 2009-12-30
EP2101782A2 (en) 2009-09-23
BRPI0718021A2 (pt) 2013-11-12
WO2008049904A2 (en) 2008-05-02
CA2664165A1 (en) 2008-05-02
WO2008049904A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
JP6761852B2 (ja) がん治療
CA2915005C (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
AU2015278765B2 (en) Intermittent dosing of MDM2 inhibitor
ES2668272T3 (es) Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación
AU2016213862B2 (en) Procaspase 3 activation by combination therapy
JP2021512101A (ja) 肥満細胞症の治療のための併用療法
CA2919996A1 (en) Methods for the treatment of solid tumors
JP6719620B2 (ja) 腫瘍選択的併用療法
CN109563088B (zh) MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
AU2019315550A1 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
JP2017530129A (ja) ツブリシン複合体を用いた癌の治療方法
KR20160135230A (ko) 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도
RU2592230C2 (ru) Апоптоз раковой клетки
CA2664148A1 (en) Vegfr3 inhibitors
TW202012000A (zh) 治療癌症之方法
US20080213275A1 (en) Use of mtki 1 for treating or preventing bone cancer
AU2007310845A1 (en) Use of MTKI 1 for treating or preventing bone cancer
RU2358736C2 (ru) Стойкая лекарственная форма из производных фенилаланина
JP6810763B2 (ja) がん治療
US20200397799A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
US20080153853A1 (en) Use of mtki 1 for treating or preventing brain cancer
CA3141072A1 (en) Methods and uses for treating cancer
WO2023239821A2 (en) Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib
CN101528234A (zh) Mtki1用于治疗或预防骨癌的用途
AU2007310842A1 (en) Use of a MT kinase inhibitor for treating or preventing brain cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period